Drug Profile
Research programme: Recombinant bone morphogenetic protein 10 - Centessa Pharmaceuticals
Alternative Names: BMP 10Latest Information Update: 25 Feb 2021
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer Centessa Pharmaceuticals
- Class Antihypertensives
- Mechanism of Action Bone morphogenetic protein receptor type II modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 16 Feb 2021 Morphogen-IX has merged with Centessa Pharmaceuticals to form Centessa Pharmaceuticals
- 28 Feb 2020 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in United Kingdom